| Old Articles: <Older 4541-4550 Newer> |
|---|
 |
Chemistry World
February 2008
Derek Lowe |
Column: In the Pipeline Does it matter whether or not a pharmaceutical company is run by a chemist?   |
The Motley Fool
January 30, 2008
Brian Lawler |
The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug. |
The Motley Fool
January 30, 2008
Brian Lawler |
Eli Lilly Is Resilient Proving that not every sector is affected by downturns, Eli Lilly released its fourth-quarter results yesterday, showing a bit of top-line growth. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Endo a CEO Shares of Endo Pharmaceutical rise after its CEO, Peter Lankau, resigns. |
Chemistry World
January 29, 2008
Richard Van Noorden |
Tiny Magnets to Repel Drug Counterfeiters A large pharmaceutical packaging company is hoping that nanotech security tags devised by a small Singaporean firm will help it combat counterfeit drugs. |
The Motley Fool
January 29, 2008
Brian Orelli |
No Weight Loss at Amylin Bulging costs related to its diabetes drug Byetta keep the drugmaker from showing a profit this quarter. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
January 29, 2008
Brian Lawler |
Acorda Rides the Wave Acorda Therapeutics announces positive clinical trial data on its lead multiple sclerosis drug. |
The Motley Fool
January 29, 2008
Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool
January 29, 2008
Brian Lawler |
BioSante's Gamble Against Generics BioSante releases more information on the pivotal studies for its lead drug. |
| <Older 4541-4550 Newer> Return to current articles. |
